Edition:
United States

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

2,673JPY
2:00am EDT
Change (% chg)

¥-6 (-0.22%)
Prev Close
¥2,679
Open
¥2,672
Day's High
¥2,687
Day's Low
¥2,655
Volume
922,900
Avg. Vol
1,020,621
52-wk High
¥2,748
52-wk Low
¥1,891

Latest Key Developments (Source: Significant Developments)

‍Mitsubishi Tanabe Pharma America says signs agreement with Option Care for national home infusion services​
Wednesday, 6 Sep 2017 08:30am EDT 

Sept 6 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:‍Mitsubishi Tanabe Pharma America says signs agreement with Option Care for national home infusion services​.‍Mitsubishi Tanabe Pharma America says agreement with Option Care Enterprises to become a national provider of home infusion services for Radicava​.  Full Article

Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Neuroderm Ltd :Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation.  Full Article

Mitsubishi Chemical Holdings consolidated subsidiary to buy NeuroDerm for about $1.1 bln
Monday, 24 Jul 2017 02:26am EDT 

July 24(Reuters) - Mitsubishi Chemical Holdings Corp <4188.T>:Says its consolidated subsidiary Mitsubishi Tanabe Pharma Corp <<<4508.T>>> will buy NeuroDerm Ltd <<>>, for about $1.1 billion (about 124.1 billion yen), $39 per share, effective October .  Full Article

Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln
Monday, 24 Jul 2017 02:00am EDT 

July 24 (Reuters) - Neuroderm Ltd :Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash.Mitsubishi Tanabe Pharma will acquire neuroderm for us$39 per share in cash.Neuroderm Ltd says currently anticipates transaction will close in Q4 of 2017.Neuroderm deal has received unanimous approval by board and implies an equity value of approximately us$1.1 billion.Special meeting of shareholders to approve transaction is expected to be held this fall.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Monday, 12 Jun 2017 02:09am EDT 

June 12 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Mitsubishi Tanabe Pharma enters into Invossa licensing agreement with Kolon Life Science
Tuesday, 1 Nov 2016 01:22am EDT 

Mitsubishi Tanabe Pharma Corp <4508.T> : Says co and Kolon Life Science have concluded a licensing agreement for Invossa, a cell therapy product for improvement of symptoms of knee osteoarthritis .According to the agreement co will acquire exclusive development and commercialization rights for Invossa in Japan.  Full Article

FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS
Tuesday, 30 Aug 2016 08:45am EDT 

Mitsubishi Tanabe Pharma <4508.T> : FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS . FDA accepts Mitsubishi Tanabe Pharma's NDA filing for Edaravone to treat ALS .Says if approved, medicine will be commercialized, under brand name Radicava, through newly formed Mt Pharma America, Inc.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook
Monday, 14 Mar 2016 02:00am EDT 

Mitsubishi Tanabe Pharma Corp:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

Mitsubishi Tanabe Pharma announces result of early-retirement program
Wednesday, 3 Feb 2016 02:00am EST 

Mitsubishi Tanabe Pharma Corp:Says 634 employees took up the offer of the early-retirement program announced on Oct. 30, 2015.Effective date of retirement is March 31.  Full Article

Mitsubishi Tanabe Pharma to offer early-retirement program
Friday, 30 Oct 2015 01:00am EDT 

Mitsubishi Tanabe Pharma Corp:To offer an early-retirement program to employees, who are above 45 years old as of April 1, 2016.Offering period from Dec. 1 to Dec. 25.Says the employees who take up the offer will retire on March 31, 2016.The company will provide retirement payment and outplacement support to the retiring employees.  Full Article

BRIEF-Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

* Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation Source text for Eikon: Further company coverage: